<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients.</p><p>Indications, patient selection and the choice of the chemotherapeutic agent are described in this manuscript, as well as an overview of the most recent literature about this topic.</p></abstract>

The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients.Indications, patient selection and the choice of the chemotherapeutic agent are described in this manuscript, as well as an overview of the most recent literature about this topic.

Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?"}

The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor...

Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Publié en ligne: 09 mars 2018

Pages: 187 - 189

Reçu: 29 sept. 2017

Accepté: 29 déc. 2017

DOI: https://doi.org/10.1515/cipms-2017-0035

Mots clés
gastric adenocarcinoma, hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal metastasis, peritoneal carcinomatosis, GASTRIPEC trial

© 2017 Beate Rau et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Publié en ligne: 09 mars 2018

Pages: 187 - 189

Reçu: 29 sept. 2017

Accepté: 29 déc. 2017

DOI: https://doi.org/10.1515/cipms-2017-0035

Mots clésgastric adenocarcinoma, hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal metastasis, peritoneal carcinomatosis, GASTRIPEC trial

© 2017 Beate Rau et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
gastric adenocarcinoma, hyperthermic intraperitoneal chemotherapy (HIPEC), peritoneal metastasis, peritoneal carcinomatosis, GASTRIPEC trial